

Cite this: *Biomater. Sci.*, 2021, **9**, 4329

## Bicyclic RGD peptides enhance nerve growth in synthetic PEG-based Anisogels†

Sitara Vedaraman,<sup>a,b</sup> Dominik Bernhagen,<sup>c</sup> Tamas Haraszti,<sup>a,b</sup> Christopher Licht,<sup>a,b</sup> Arturo Castro Nava,<sup>a,b</sup> Abdolrahman Omidinia Anarkoli,<sup>a,b</sup> Peter Timmerman<sup>b,c,d</sup> and Laura De Laporte<sup>a,b,e</sup>

Nerve regeneration scaffolds often consist of soft hydrogels modified with extracellular matrix (ECM) proteins or fragments, as well as linear and cyclic peptides. One of the commonly used integrin-mediated cell adhesive peptide sequences is Arg-Gly-Asp (RGD). Despite its straightforward coupling mechanisms to artificial extracellular matrix (aECM) constructs, linear RGD peptides suffer from low stability towards degradation and lack integrin selectivity. Cyclization of RGD improves the affinity towards integrin subtypes but lacks selectivity. In this study, a new class of short bicyclic peptides with RGD in a cyclic loop and 'random screened' tri-amino acid peptide sequences in the second loop is investigated as a biochemical cue for cell growth inside three-dimensional (3D) synthetic poly(ethylene glycol) (PEG)-based Anisogels. These peptides impart high integrin affinity and selectivity towards either  $\alpha_v\beta_3$  or  $\alpha_5\beta_1$  integrin subunits. Enzymatic conjugation of such bicyclic peptides to the PEG backbone enables the formulation of an aECM hydrogel that supports nerve growth. Furthermore, different proteolytic cleavable moieties are incorporated and compared to promote cell migration and proliferation, resulting in enhanced cell growth with different degradable peptide crosslinkers. Mouse fibroblasts and primary nerve cells from embryonic chick dorsal root ganglions (DRGs) show superior growth in bicyclic RGD peptide conjugated gels selective towards  $\alpha_v\beta_3$  or  $\alpha_5\beta_1$ , compared to monocyclic or linear RGD peptides, with a slight preference to  $\alpha_v\beta_3$  selective bicyclic peptides in the case of nerve growth. Synthetic Anisogels, modified with bicyclic RGD peptides and containing short aligned, magneto-responsive fibers, show oriented DRG outgrowth parallel to the fibers. This report shows the potential of PEG hydrogels coupled with bicyclic RGD peptides as an aECM model and paves the way for a new class of integrin selective biomolecules for cell growth and nerve regeneration.

Received 2nd December 2020,  
Accepted 16th February 2021

DOI: 10.1039/d0bm02051f

rsc.li/biomaterials-science

## Introduction

The native neuronal tissue is soft (0.1–1 kPa) and consists of a highly ordered microarchitecture to enable connections between neurons and their supporting cells to form a func-

tional neural network.<sup>1</sup> Efficient nerve regeneration in an artificial extracellular matrix (aECM) is achieved by mimicking the extracellular matrices (ECM) with three-dimensional (3D) scaffolds where the cells inside the scaffold experience a combination of chemical, physical, and architectural cues.<sup>2,3</sup> *Ex vivo* mimicry of biological systems is established to create relevant models and micro-environments that enable cells to adhere, proliferate and migrate either by squeezing through the aECM (amoeboid) or by degrading their local environment by secreting proteases (mesenchymal).<sup>4</sup> Most of the studied ECM mimicking neural niches and 3D scaffolds are based on endogenous protein sources, such as collagen,<sup>5</sup> fibrin,<sup>6,7</sup> hyaluronic acid,<sup>8,9</sup> or a combination of these.<sup>10,11</sup> Although proteinaceous gels or scaffolds offer a natural environment for cell growth, their batch to batch variability and lack of controlled properties are limiting factors. On the other hand, scaffolds made from synthetic polymers or other macromolecules are reproducible, more resistant to immunogenic reactions, and easy to vary in properties, such as stiffness,

<sup>a</sup>DWI Leibniz Institute for Interactive Materials, Forckenbeckstrasse 50, 52074 Aachen, Germany

<sup>b</sup>Institute for Technical and Macromolecular Chemistry, RWTH Aachen, Worringerweg 1-2, 52074 Aachen, Germany. E-mail: delaporte@dwil.rwth-aachen.de

<sup>c</sup>Pepsican Therapeutics, Zuidersluisweg 2, 8243 RC Lelystad, the Netherlands

<sup>d</sup>Van't Hoff Institute for Molecular Sciences, University of Amsterdam, Science Park 904, 1098 XH Amsterdam, the Netherlands

<sup>e</sup>Institute of Applied Medical Engineering, RWTH University, Pauwelsstraße 20, 52074 Aachen, Germany

† Electronic supplementary information (ESI) available: Additional supplementary data on 3D homogeneous distribution of fibroblasts and DRGs in PEG hydrogels, circularity and edge effect quantification, proliferation assay comparing Q-RGD and K-RGD and comparative study of fibroblast cell growth in 3D PEG hydrogels with Q-RGD and FN\*. See DOI: 10.1039/d0bm02051f



degradability, architecture, biomolecule modification, *etc.*<sup>12</sup> To combine the advantages of both natural and synthetic building blocks, hybrid materials are often employed. Arginylglycylaspartic acid (Arg-Gly-Asp or RGD) is the smallest integrin recognizable ligand present *in vivo*, which is widely used to induce cell adhesion in synthetic scaffolds.<sup>13</sup> For example, elastin-like proteins (ELP) with controlled RGD ligand density and optimized scaffold stiffness enabled neurite outgrowth of chick dorsal root ganglions (DRGs).<sup>14</sup> Semi-synthetic scaffolds, prepared from PEGylated albumin or PEGylated fibrinogen enabled nerve growth at low concentrations of PEG (1.6 w/v% and 2.3 w/v%, respectively) with 0.8 w/v% of the respective proteins.<sup>15</sup> Besides RGD, the laminin-derived adhesion peptide IKVAV is often employed to induce vascularization and innervation, for example in composite hydrogels consisting of elastin-like polypeptides and PEG, creating a microporous environment with controlled mechanical properties.<sup>16</sup> In the case of non-endogenous sources, proteinaceous gels, such as silk<sup>17</sup> and alginate<sup>18</sup>-based hydrogels provide a promising environment as a 3D neuronal scaffold.

In the case of polymeric hydrogel scaffolds, the mechanical properties can be varied by the composition, structure, molecular weight, reaction mechanism, and concentration of the pre-polymer, and optimized to support nerve growth and axon protrusion.<sup>19,20</sup> Inside these constructs, spatial distribution<sup>14,21</sup> of integrin-binding ligands and the internal structure are crucial factors in bio-mimicking the native cell microenvironment. Designing hydrogels with large pores that facilitate perfusion of growth factors and nutrients,<sup>22</sup> while at the same time permitting temporally controlled degradation is primordial to promote cell proliferation and enable cell motility and scaffold invasion.<sup>23</sup> Among the several reported polymeric hydrogel systems, PEG-based networks offer a biocompatible microenvironment for cells with a low risk of immune reaction. By using degradable crosslinks, the degradation products can be eliminated from the body *via* natural biochemical mechanisms.<sup>24–26</sup> The PEG system used in this report employs an enzymatic crosslinking and bio-conjugation method, inspired by fibrin clotting,<sup>27</sup> while degradation moieties are included in the backbone to enable proteolytic degradation by matrix metalloproteases (MMPs).<sup>24,28</sup> These MMP sensitive domains in the crosslinker degrade when cells produce MMPs, resulting in gel degradation on cell-demand and providing space for growing cell populations. Such a system has been reported by our group to promote 3D nerve growth when a specially designed fibronectin fragment FNIII9\*-10/12-14 was coupled inside the gel.<sup>20</sup> Compared to linear RGD, much lower concentrations of the fragment were sufficient to support cell growth. FNIII9\*-10/12-14 has previously demonstrated to enhance wound and bone regeneration when bound to a fibrin gel, likely due to the synergistic effect of providing integrin binding domains adjacent to growth factor binding domains.<sup>29</sup> In the case of RGD coupling to a synthetic fibrin-mimicking PEG gel, Ehrbar *et al.* determined the binding efficiency *via* the transglutaminase reaction using release studies by reverse phase chromatography and mass spec-

troscopy, resulting in ~72% RGD binding efficiency for 5 wt/v% gels in the case of 4.3% RGD peptides of total PEG-K arms.<sup>30</sup> We previously translated these gels with FNIII9\*-10/12-14 to Anisogels to create anisotropy imparting gels by incorporating magneto-responsive rod-shaped microgels or short fibers and aligning them along external magnetic field lines to promote unidirectional neurite extension.<sup>20</sup>

Integrin binding domains, incorporated inside aECMs are involved in bidirectional transmembrane signalling between cells and their environment and play an important role in cell growth.<sup>31</sup> Integrins are involved in the regulation of physiological processes such as migration, proliferation, survival, and apoptosis. The focal adhesion mechanisms between the ECM ligand and the integrin receptor heterodimers, consisting of  $\alpha$  and  $\beta$  integrin subunits, have been extensively studied.<sup>32,33</sup> Linear RGD peptides, cyclic RGD peptides, and peptidomimetic ligands have evolved progressively for binding integrin subunits.<sup>34</sup> Flanking linear RGD peptides with amino acids, such as glycine (G) at the N terminus and serine (S) at the C terminus, results in a decrease in half-maximum inhibitory concentration ( $IC_{50}$ ) values by 3 and 4 folds for  $\alpha_v\beta_3$  and  $\alpha_5\beta_1$  integrin subunits, respectively.<sup>35</sup> Lower  $IC_{50}$  values indicate a higher affinity to integrin subunits and the lowest  $IC_{50}$  value is observed for heptapeptide GRGDSPK, which is 7 folds lower than for tripeptide RGD in the case of  $\alpha_v\beta_3$ .<sup>35</sup> Similarly, the cyclization of linear RGD peptides (RGDfK) and incorporation of one D-amino acid residue between Asp (D) and Lys (K) improves affinity to integrin subunits and increases stability towards enzymatic degradation.<sup>35,36</sup> Monocyclic RGD peptides show moderate to low  $IC_{50}$  values towards multiple integrin subunits, such as  $\alpha_v\beta_3$ ,  $\alpha_v\beta_5$ ,  $\alpha_v\beta_6$ , and  $\alpha_5\beta_1$ . The lowest  $IC_{50}$  values are observed for  $\alpha_v\beta_3$  subunits and cyclization improves integrin  $\alpha_v\beta_3$  binding affinity in the range of 1.5–6.0 nM and integrin  $\alpha_5\beta_1$  binding affinity in the range of 141–236 nM.<sup>35</sup> Similar to flanking in linear RGD, flanking in cyclic RGD peptides with linear polyproline improves cell spreading and focal adhesions in rat embryo fibroblasts in comparison to other spacers like PEG.<sup>37</sup> Another class of high affinity and selective integrin-binding ligands are the peptidomimetics, which can distinguish between different integrin subtypes *in vitro* and *in vivo*.<sup>38,39</sup>

It is important to understand the role of integrin-mediated adhesion to its corresponding ligands in the ECM for achieving directed cell fate in tissue engineering applications. For example, the ability of cells to sense the mechanical properties of its fibronectin based ECM is mediated by the synergy between the  $\alpha_5\beta_1$  and  $\alpha_v$ -class integrin subunits.<sup>40</sup> Similarly, the inter-dependence of integrins ( $\alpha_5\beta_1$ ,  $\alpha_v\beta_3$ ) employed during focal adhesions is explored on 2D platforms with integrin specific RGD-coupled gold nanoparticles on PEG gels. The study revealed that during focal adhesion, the recruitment of  $\alpha_v\beta_3$  integrins occurs on patterned substrates that are exclusive for  $\alpha_5\beta_1$ , but the *vice versa* is not true.<sup>41</sup> In addition, 3D hyaluronan acid hydrogels with specific integrin activation ( $\alpha_3/\alpha_5\beta_1$ ) induced sprouting in an endothelial cell angiogenic model *in vitro* and enabled the formation of non-leaky blood



vessels in stroke models.<sup>8</sup> Such examples show the importance of integrin-mediated cell adhesion and migration, which in turn determines cell fate.


In this report, a new class of integrin selective engineered bicyclic peptides with one loop containing the integrin-binding RGD peptide is employed to study neuronal growth in 3D PEG-based hydrogels and Anisogels. These peptides have demonstrated greater conformational rigidity, metabolic stability, and most importantly, high integrin selectivity. The primary loop consists of an RGD peptide flanked with cysteine residues that bind to a tri-covalent scaffold (1,3,5-tris(bromomethyl)benzene). The secondary loop consists of a tri amino-acid sequence, which is screened using a 'random approach' and imparts the potential to affect the RGD selectivity towards different integrin subunits ( $\alpha_v\beta_3$  or  $\alpha_5\beta_1$ ).<sup>42,43</sup> Elastin-like recombinamers (ELR), produced with recombinant proteins and coupled with bicyclic RGD peptides selective for  $\alpha_5\beta_1$  show an increase in HUVEC proliferation at early periods of culture.<sup>44</sup> Here, we describe for the first time the effect of bicyclic RGD peptides for nerve growth in synthetic 3D PEG hydrogels to study the affinity towards selective integrin sites. Soft, synthetic, degradable multi-arm PEG hydrogels are enzymatically crosslinked using transglutaminase and conjugated with different bicyclic RGD peptides. Domains cleavable by MMP 1, MMP 2, and plasmin are incorporated in the PEG precursors to enable on cell-demand degradation at the cross-linking arms. The MMP 1 and MMP 2 sensitive domains enable extensive cell growth inside the hydrogel. Expansion of both mouse fibroblasts and primary nerve cells from chick DRGs is investigated and compared with linear and monocyc-

lic RGD and a specific fibronectin fragment FNIII9\*-10/12-14<sup>29</sup> (FN\*). Bicyclic RGD conjugated gels show superior nerve and fibroblast growth. Also, cell growth and innervation in PEG gels are dependent on the type of proteolytic cleavable MMP-sensitive peptide present in the crosslinker. Finally, fully synthetic Anisogels are prepared by mixing and orienting short, magneto-responsive polycaprolactone (PCL) fibers (diameter  $\sim 5 \mu\text{m}$ , length  $\sim 50 \mu\text{m}$ , 1 vol%) before crosslinking of the surrounding PEG hydrogels, modified with the bicyclic peptides and optimal degradation domain VPMS↓MRGG (K<sub>2</sub>). Embedded DRGs inside Anisogels, tethered with bicyclic RGD peptides (K-P2 RGD), linear RGD (K-RGD) and fibronectin fragment (FN\*) demonstrate unidirectional nerve growth.

## Results and discussion

### Designing RGD conjugated PEG hydrogels

Nerve and fibroblast cell growth in synthetic PEG hydrogels is compared among bicyclic peptides and standard RGD peptides, commonly used for biomaterial development. The RGD peptides are tethered to the PEG hydrogels (Fig. 1a) either by its amine in the lysine (K), its amide in glutamine (Q), or *via* the amine from the N terminus of any unmodified RGD peptide. The RGD peptides with K or Q residues bind to the arms PEG-Q or PEG-K, respectively. Transglutaminase reaction between the Q and the K residues is initiated in the presence of an enzyme (activated FXIII), resulting in the formation of an iso-peptide bond.<sup>45</sup> The multiple arms in PEG facilitate cross-linking and bio-conjugation simultaneously. PEG polymer is



**Fig. 1** PEG hydrogel system. (A) Schematic of PEG hydrogel system with MMP cleavable arms in PEG-K precursor and RGD peptide conjugation via its K and Q residues. (B) Representative bicyclic RGD peptides P1 and Bicyclic RGD peptide P2, selective for integrin  $\alpha_5\beta_1$  and  $\alpha_v\beta_3$  respectively. (C) Summarized peptide sequences for bicyclic, mono-cyclic, linear RGD peptides indicating selective integrin target. (D) Proteolytic cleavable amino acid sequences incorporated in the 8-arm PEG-K precursor.



used at 1 wt/v% to fabricate hydrogels with a storage modulus of  $\sim 10$  Pa,<sup>20</sup> to which a fixed concentration (100  $\mu$ M) of RGD peptide is conjugated. In a previous report, we demonstrate superior cell growth using this RGD concentration.<sup>20</sup> The proteolytic cleavable sites are incorporated in the arms of PEG-K; PEG-K<sub>1</sub>: FKGG-GPQG↓IWGQ-PEG (K<sub>1</sub>), PEG-K<sub>2</sub>: FKGG-VPMS↓MRGG-PEG (K<sub>2</sub>), PEG-K<sub>3</sub>: FKGG-K↓K↓GHK↓LHL-PEG (K<sub>3</sub>), PEG-K<sub>ND</sub>: FKGG-GDQGIAGF-PEG (K<sub>ND</sub>) (Fig. 1d), where K<sub>ND</sub> is an 8 amino acid sequence not degraded by MMPs. These MMP sensitive domains are cleaved by proteases.<sup>24,46</sup>

Mixing the precursor solution with the cells and controlling the crosslinking rate by the concentration of activated Factor XIII (FXIIIa) enables 3D encapsulation of cells. Bicyclic RGD peptides, engineered by Bernhagen *et al.*, contain two loops, consisting of an RGD sequence and integrin selectivity imparting sequence, where Ala-Trp-Gly (AWG) results in selectivity towards  $\alpha_5\beta_1$  and loop His-Pro-Gln (HPQ) leads to selectivity towards  $\alpha_v\beta_3$  (Fig. 1b). Bicyclic RGD peptides (Fig. 1c) (K-linker-C<sub>T3</sub>RGD<sub>C</sub>T<sub>3</sub>AWG<sub>C</sub>T<sub>3</sub>,<sup>43</sup> NQEQVSPL-C<sub>T3</sub>RGD<sub>C</sub>T<sub>3</sub>AYJ<sub>C</sub>T<sub>3</sub>G, K-linker-C<sub>T3</sub>HPQ<sub>C</sub>T<sub>3</sub>RGD<sub>C</sub>T<sub>3</sub>,<sup>42</sup> NQEQVSPL<sub>C</sub>T<sub>3</sub>HPQ<sub>C</sub>T<sub>3</sub>RGD<sub>C</sub>T<sub>3</sub>G), cyclic RGD peptides (cyclo-RGDfK,<sup>35</sup> cyclo-DfK[K-linker]RG), and linear RGD peptides (K-linker-GRGDS, NQEQVSP<sub>LRGDS</sub>PG, GRGDS<sup>35</sup>) are used as cell adhesive domains in this study with controls, such as scrambled second loops (K-linker-C<sub>T3</sub>RGD<sub>C</sub>T<sub>3</sub>WGAC<sub>T3</sub>, K-linker-C<sub>T3</sub>PQHc<sub>T3</sub>RGD<sub>C</sub>T<sub>3</sub>) and scrambled RGD peptides (K-linker-C<sub>T3</sub>GDRc<sub>T3</sub>AWG<sub>C</sub>T<sub>3</sub>, K-linker-C<sub>T3</sub>HPQ<sub>C</sub>T<sub>3</sub>GRD<sub>C</sub>T<sub>3</sub>). Fibronectin fragment FNIII 9\*-10/12-14 is used as positive control and PEG gels without RGD as another negative control.

### Influence of RGD peptides on fibroblast growth

Hydrogels conjugated with RGD peptides enable the spatial distribution of integrin-binding ligands for cell adhesion, spreading, and proliferation. These peptides are classified based on their structure as linear, cyclic, and bicyclic, reporting an increase in integrin affinity and selectivity based on IC<sub>50</sub> from former to the latter.<sup>35,43,47</sup> L929 mouse fibroblasts are encapsulated within the hydrogel at a fixed cell concentration. 3D cell growth in multiple planes is quantified after staining for actin filaments and imaging as z-stacks. A 200  $\mu$ m z-stack image (Fig. S1†) of cells in a K-P2 conjugated hydrogel is represented by a color-coded depth profile, showing homogeneous cell distribution. Cells show different morphologies depending on the type of RGD peptide tethered to the hydrogels (Fig. 2a).


The cells inside the hydrogels with bicyclic (K-P1, K-P2) and monocyclic (K-cRGD) RGD peptides spread and stretch to form network-like structures, in contrast to cells in gels with linear RGD (K-RGD) or no RGD. For hydrogels, modified with linear RGD, only some cells stretch, while others are more rounded with small protrusions (white arrows) resembling filipodia. In the control condition without RGD, most cells appear rounded, even though some cells are able to spread, likely due to their natural production of ECM proteins and proteases. The superimposed z stacks of the actin-stained images are compared for their cell invasion area (%) per field of view

(Fig. 2b). K-P2 is the only peptide that statistically leads to similar cell invasion, compared to FN\*, suggesting that the fibroblasts used in this culture may be more sensitive to  $\alpha_v\beta_3$  binding domains. This is in agreement with the fact that the mono-cyclic peptide (more selective to  $\alpha_v\beta_3$ <sup>35</sup>) leads to better cell invasion compared to the linear RGD peptide, which has 5 $\times$  lower affinity to  $\alpha_v\beta_3$  and binds to both  $\alpha_v\beta_3$  and  $\alpha_5\beta_1$ .<sup>35</sup> In addition, none of the RGD peptides have the synergistic domain PHSRN, which is required for efficient  $\alpha_5\beta_1$  binding.<sup>48</sup> This could explain the fact that the bicyclic peptide P2 shows a higher binding affinity towards  $\alpha_v\beta_3$  (IC<sub>50</sub>: 30 nM<sup>47</sup>) compared to peptide P1 towards  $\alpha_5\beta_1$  (IC<sub>50</sub>: 173 nM<sup>43</sup>).

Among the bicyclic RGD peptides tethered *via* K, the peptide K-P2 show significantly higher cell invasion compared to K-P1, however, no such difference is observed in the case of bicyclic RGD tethered *via* Q. In addition, the K-P2 peptide leads to higher cell invasion compared to Q-P2, with the K-peptide having the shorter linker. Factors affecting the performance of a bicyclic peptide leading to the differences in cell behaviour can thus be attributed towards their Q or K residue peptide linkers, spatial availability of RGD peptide, and binding efficiency. When comparing the RGD peptides with fibronectin fragment FNIII9\*-10/12-14 (5  $\mu$ M, FN\*),<sup>20</sup> the fragment results in a more dense cell network. We reason that FN\* provides a more natural ECM mimicking environment, compared to the RGD peptides, as the RGD sequence in FNIII10 can work together with its synergistic PHSRN sequence in FNIII9\*,<sup>48</sup> which is not present in any of the peptides used. In this experiment, linear K-RGD is employed to compare with the K-cRGD as both Q-RGD (100  $\mu$ M) and K-RGD (100  $\mu$ M) have a similar RGD potency when a proliferation assay is performed with L929 fibroblasts grown on thin PEG substrates (Fig. S2†). Further, a comparison of cell invasion in 3D gels, modified with Q-RGD (100  $\mu$ M) or FN\* (5  $\mu$ M), leads to a similar Q-RGD *vs.* FN\* ratio (ratio: 0.59) (Fig. S3†) as when comparing K-RGD (100  $\mu$ M) with 5  $\mu$ M FN\* (ratio: 0.57) (Fig. 2b).

In parallel to the cell invasion area (%), which is a function of cell proliferation inside the hydrogels, the shape factors of the invading cells is investigated by quantifying the *circularity* and *edge effect* of the cells or cell clusters, which account for the shape, as well as the size of the cells. Since most of the hydrogel conditions support cell spreading, it is difficult to image single cells inside the network of fibroblasts. Hence, a *circularity* analysis tool (Fig. S4†) is employed to compute the perimeter of single cells or cell clusters. *Circularity* measures the irregular shape of spread cells and cell clusters, with a *circularity* of 1.0 indicating a rounded cell and a well-spread cell being represented by a circularity closer to 0. All bicyclic RGD peptides Q-P1, Q-P2, K-P1, and K-P2 show significantly lower *circularity* (0.10 to 0.12) compared to cyclic RGD (K-cRGD, 0.16) and linear (K-RGD, 0.19; Q-RGD, 0.15) (Fig. 2c, Fig. S3†). FN\* still has the lowest *circularity* (0.09), validating the high network-like cell spreading observed in the fluorescent micrographs. No statistical difference in *circularity* is observed between the bicyclic peptides, inferring to the possible recruit-





**Fig. 2** Different RGD peptides and fibronectin fragment influencing fibroblast spreading and growth in PEG gels. (A) Mouse fibroblast cells immunostained for actin filaments in PEG hydrogels with bicyclic RGD peptides tethered via Q (Q-P1, Q-P2) or K (K-P1, K-P2) residues, monocyclic RGD (K-cRGD), linear RGD (K-RGD), fibronectin fragment FNIII9\*-10/12-14 (FN\*) and no RGD as control. White arrows indicate circular non-spread cells (B) Cell invasion area (%) of superimposed z-stack fluorescent micrographs. Quantification of shape factors using (C) circularity, and (D) edge effect of cells inside PEG gels modified with different RGD peptides. Data presented as mean + s.d. and statistical significance performed using one-way ANOVA with Bonferroni comparison (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ).

ment of multiple integrins during fibroblast cell adhesion and migration. Multiple integrin receptors contribute during focal adhesion kinase mediated fibroblast migration, such as  $\alpha_5\beta_1$

and  $\alpha_4\beta_1$  playing a major role and  $\alpha_v\beta_3$ ,  $\alpha_v\beta_6$ , and  $\alpha_v\beta_8$  a minor role on fibronectin.<sup>49</sup> Similarly, the edge detection tool – *edge effect* – computes the ‘perimeter’ to ‘square root of surface



area' ratio, which is directly proportional to cell spreading (Fig. 2d, Fig. S3c†). A higher ratio reflects more spread cells. However, if multiple cells are clustered together or cells in multiple planes are overlapping with one another in the superimposed images, an increase in cell area is associated with a reduction in the *edge effect* and an increase in *circularity* due to hidden perimeters inside the clusters. While *circularity* considers the shape factor, the *edge effect* in addition considers how much the cells are expressing local protrusions (Fig. S4a†). FN\* showed the largest *edge effect* followed by bicyclic RGD peptides, Q-P1, Q-P2, and monocyclic K-cRGD peptides. A significant increase in *edge effect* is observed for bicyclic Q-P1 compared to the linear K-RGD. Similarly, a significant increase in *edge effect* is observed for FN\* compared to the bicyclic K-P1, K-P2, monocyclic K-cRGD, and linear K-RGD. Therefore, the combined reduction in *circularity* and increase in *edge effect* (Fig. S4b†) demonstrate the higher cell spreading for bicyclic RGD peptides compared to linear and monocyclic RGD peptides.

### Influence of different degradable MMP sensitive domains on fibroblast growth

To render the hydrogel degradable, MMP sensitive domains are incorporated in the arms of the PEG-K precursors. This enables on cell-demand hydrogel degradation as the cells secrete the enzymes needed to cleave the crosslinks. This creates physical space for the cells to migrate and proliferate.<sup>25</sup> PEG gels fabricated with di-cysteine K<sub>1</sub> or K<sub>2</sub> peptides as linear degradable crosslinkers previously reported an increase in cell invasion for K<sub>2</sub> in comparison to K<sub>1</sub> in the case of mouse myofibroblasts, owing to its high catalytic constant  $k_{\text{cat}}$  for MMP1 and MMP2.<sup>24</sup> Similarly, K<sub>3</sub> derived from Secreted Protein Acidic and Rich in Cysteine (SPARC) has been demonstrated to be degraded by plasmin, while its high  $k_{\text{cat}}$  enhanced cell invasion in PEG gels.<sup>46</sup> Here, the growth of mouse fibroblasts is investigated in bicyclic K-P2 RGD-modified PEG hydrogels depending on these three proteolytic sensitive domains (K<sub>1</sub>, K<sub>2</sub>, K<sub>3</sub>), and compared to a non-degradable domain (K<sub>ND</sub>) and no RGD. The fluorescent micrographs stained for actin (Fig. 3a) and their corresponding cell invasion areas (%) (Fig. 3b) indicate a significantly higher level of cell growth in PEG gels crosslinked with K<sub>1</sub> or K<sub>2</sub> (>17.5%) degradable domains and tethered with bicyclic K-P2 RGD peptide, when compared to their controls without RGD (<13%).


The lower levels of cell growth in K<sub>1</sub> and K<sub>2</sub> gels in the absence of RGD indicate that the cells partly try to rescue themselves by secreting both ECM proteins and proteases. These observations are in agreement with a previous report from our research group where an increase in native fibronectin production by fibroblast cells was observed in the presence of bioinert microgels inside 3D Anisogel, compared to RGD-functionalized microgels.<sup>50</sup> A low cell invasion area is observed for K<sub>3</sub> gels with (~13.5%) and without (~2%) K-P2 RGD peptide, with the K<sub>3</sub>, no RGD showing exclusively rounded single cells in 3D. Although Patterson *et al.* reported improved cell invasion in gels made with K<sub>3</sub> peptide, the results

obtained here are not demonstrating enhanced cell growth. The PEG gels prepared with K<sub>ND</sub> show a low cell invasion area (%) and a high *circularity* (Fig. 3c), indicating low cell spreading and moderate cell proliferation. However, in the presence of K-P2 RGD, the cells appear more clustered, which suggests that the presence of RGD does promote cell proliferation but due to lack of open space, spreading is limited. In the case of the *edge effect* (Fig. 3d), the hydrogels with degradable environment show higher edge effects for cells in gels modified with K-P2 compared to no RGD. Hydrogels with crosslinkers K<sub>1</sub> and K<sub>2</sub> have the highest edge effect offering a favourable environment for cell growth and spreading. Overall, the multi-parameter analysis reveals high fibroblast growth in hydrogels crosslinked with K<sub>1</sub> or K<sub>2</sub> degradable domains in the presence of bicyclic K-P2 RGD peptides, in comparison to K<sub>3</sub> and K<sub>ND</sub>, highlighting the importance of degradable domains in par with the cell adhesive ligands when developing artificial ECM scaffolds for functional cell growth.

### Influence of RGD peptides on nerve growth

To study the effect of RGD peptides on nerve growth, DRGs are encapsulated in PEG precursors with a fixed RGD concentration of 100  $\mu\text{M}$ . The explants are cultured in PEG-based hydrogels, modified with bicyclic RGD (K-P1, K-P2, Q-P1, Q-P2), linear RGD (K-RGD, Q-RGD, RGD), or monocyclic RGD (K-cRGD, cRGD), and controls (no RGD, FN\*) hydrogels. DRGs are cultured for 7 days, fixed, immunostained for  $\beta$ -tubulin fluorescent markers, and imaged with a minimum z-stack size of 200  $\mu\text{m}$  (Fig. S5†). Neurite outgrowth (Fig. 4a) is analyzed using an image processing platform developed in-house to compute the nerve length at half-maximum density and the longest distance travelled by nerve. The fluorescent micrographs of bicyclic RGD peptide (K-P1, K-P2) show superior nerve growth in length (at half-maximum density) (~600  $\mu\text{m}$ ) compared to monocyclic (K-cRGD, 420  $\mu\text{m}$ ) and linear (K-RGD, 270  $\mu\text{m}$ ), while comparable extension is observed among the bicyclic RGD peptides and FN\* (520  $\mu\text{m}$ ). Consistent with the bright field images, the negative controls without RGD show minimal innervation of the PEG gels. This can be rationalized by the production of ECM proteins and proteases as discussed in the previous section. To quantify nerve growth, the distance of neurite extensions from the edge of the DRG is measured radially, until the distance where the neurite density drops to half of the maximum density (Fig. 4b). This reveals superior neurite growth in bicyclic RGD gels (K-P1, Q-P2, and K-P2) compared to the hydrogels, modified with linear RGD (K-RGD). Interestingly, neurite growth in gels, tethered with bicyclic RGD *via* K residues shows longer neurite extensions at half-maximum density compared to their corresponding bicyclic RGD peptides conjugated *via* Q residues. Interestingly, this difference is only observed for bicyclic peptide selective towards  $\alpha_5\beta_1$  whereas, no such major difference nerve growth is observed between bicyclic peptide selective for  $\alpha_v\beta_3$ . In addition, bicyclic RGD peptides with integrin selectivity towards  $\alpha_5\beta_1$  or  $\alpha_v\beta_3$  show significantly better nerve growth compared to bicyclic peptides with a scrambled secondary






**Fig. 3** MMP sensitive domains influencing fibroblast growth in PEG gels. (A) Mouse fibroblast cells immunostained for actin filaments in PEG hydrogels with different MMP sensitive domains ( $K_1$ ,  $K_2$ ,  $K_3$ , and KND) and bio-functionalized with 100  $\mu$ M bicyclic K-P2 RGD peptides or no RGD as control. (B) Cell invasion area (%) of superimposed z-stack of fluorescent micrographs. Quantifying cell shape using (C) circularity and (D) edge effect tools. Data presented as mean + s.d. and statistical significance performed using one-way ANOVA with Bonferroni comparison (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ).

loop, which imparts integrin selectivity, highlighting the influence of integrin selectivity in nerve growth. Scrambled RGD peptides (RDG) in the first loop also lead to worsened neurite outgrowth. The neurite growth at half maxima for Q-RGD

( $\sim 450 \mu$ m) is comparable to that of the monocyclic RGDs but is not significantly different than the two other linear RGD peptides. Enhanced neurite length at half-maximum density is observed for bicyclic RGD peptides (K-P1, Q-P2, K-P2) in com-





**Fig. 4** Innervation of PEG gels modified with different RGD peptides and MMP sensitive domains. (A) Neurite outgrowth from DRGs in PEG hydrogels tethered with various RGD peptides, fibronectin fragment FN\*, and full-length fibronectin. (B) Neurite length at half-maximum density for different RGD peptides and its scrambled sequences, compared to FN\*. (C) Longest distance travelled by nerve for RGD peptides, compared to FN\*. (D) Neurite length at half-maximum density and the longest distance travelled in PEG gels with different MMP sensitive domains (K<sub>1</sub>, K<sub>2</sub>, K<sub>3</sub>, and KND), and bio-functionalized with bicyclic K-P2 RGD peptides. Data presented as mean + s.d. and statistical significance performed using one-way ANOVA with Bonferroni comparison (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ).





parison to our previously optimal condition FN\* (5  $\mu\text{M}$ ),<sup>20</sup> however, no statistical significance is observed. Such enhanced nerve growth is likely attributed towards the spatial cyclic conformation of the RGD loop in combination with the integrin selective secondary loop.

Next to the neurite length at half-maximum density, the longest distance travelled by nerve inside the gels is compared among the different RGD-tethered hydrogels (Fig. 4c) with both parameters demonstrating similar trends. The longest neurite outgrowth distance (longest distance travelled by nerve) of  $\sim 1200$   $\mu\text{m}$  is observed for bicyclic RGD peptide (K-P2), selective for  $\alpha_v\beta_3$  integrin subunits, which is significantly longer than for linear RGD peptides K-RGD ( $\sim 600$   $\mu\text{m}$ ) and RGD ( $\sim 500$   $\mu\text{m}$ ). These results are in compliance with our previous observations of dissociated DRGs cultured on 2D sPEG hydrogels, where a larger decrease in nerve growth is observed when  $\alpha_v$  integrins are blocked relative to  $\alpha_5$  integrins, revealing the importance of  $\alpha_v$  integrins in nerve growth. Similarly, integrin  $\alpha_v\beta_3$  is reported to bind an RGD sequence in immunoglobulin Ig6 to promote neurite outgrowth in DRGs and retinal cells.<sup>51</sup> Also, cellular migration of avian neural crest cells involves interaction between integrin  $\alpha_v\beta_3$  and vitronectin,<sup>52</sup> while an upregulation in  $\alpha_v\beta_3$  is reported on astrocytes post-ischemia.<sup>53</sup>

### Influence of degradable MMP sensitive domains on nerve growth

The different scaffold degradation domains are also investigated for neurite growth. Similar to the fibroblast culture, three proteolytic sensitive domains ( $K_1$ ,  $K_2$ ,  $K_3$ ) and one non-degradable domain ( $K_{\text{ND}}$ ) are investigated in hydrogels modified with bicyclic RGD peptides (K-P2) (Fig. 4d). The neurite length at half-maximum density in K-P2 tethered gels with  $K_1$  and  $K_2$  crosslinkers is significantly longer in comparison to  $K_{\text{ND}}$  gels with K-P2. Among  $K_1$  and  $K_2$  with K-P2, longer neurite growth is observed for  $K_2$ , however, no statistical significance between them is computed. Although  $K_3$  is degradable by plasmin, it shows comparable nerve length to the non-degradable  $K_{\text{ND}}$ . In addition to neurite length at half-maximum density, the longest distance travelled by nerve is quantified for these gels, revealing a similar trend with  $K_2$  gels conjugated with K-P2 RGD with a distance travelled by  $\sim 1300$   $\mu\text{m}$ , followed by  $K_1$  gels with K-P2 RGD with  $\sim 1200$   $\mu\text{m}$  (Fig. 4d). Both  $K_3$  and  $K_{\text{ND}}$  hydrogels, conjugated with K-P2 RGD, enable their longest travelled nerve up to  $\sim 900$   $\mu\text{m}$  and  $\sim 700$   $\mu\text{m}$ , respectively.

### Oriented nerve growth using anisometric magneto-responsive short PCL fibers

Among the investigated RGD bicyclic peptides and different proteolytically degradable domains, K-P2 RGD modified MMP based  $K_2$  PEG gels lead to the best nerve growth. Therefore, this combination is employed to prepare synthetic Anisogels with short magneto-responsive polycaprolactone (PCL) fibers (diameter of  $\sim 5$   $\mu\text{m}$  and length of  $\sim 50$   $\mu\text{m}$ ), which are incorporated at a concentration of 1 v/v% and aligned in the pres-

ence of a low external magnetic field (50 mT) before cross-linking of the surrounding PEG gel.<sup>20</sup> The short anisometric fibers act as directional guidance cues, function as physical barriers, and induce mechanical anisotropy in the hydrogel, to trigger nerves to grow parallel to their orientation, resulting in neurite alignment. K-P2 modified Anisogels are compared with linear (K-RGD) and fibronectin fragment (2  $\mu\text{M}$ , FN\*) and their respective controls without short fibers. Magnetically oriented fibers resulted in highly aligned neurites (Fig. 5a). The dimensions of the fibers and their innate surface properties are known to affect the cell adhesion and alignment of cells and nerves.<sup>54,55</sup> Neurite orientation is analyzed with defined anisometric orientation kernels resulting in a range of orientation distributions between  $-90^\circ$  to  $+90^\circ$ . K-P2, K-RGD, and FN\* all have a narrow distribution of aligned nerve growth with maxima around  $0^\circ$  (Fig. 5b). Bright-field images superimposed with tubulin stained (yellow) Anisogels show nerve growth along the direction of the fibers (Fig. 5c).

All of the Anisogels studied showed superior nerve alignment compared to their respective controls without oriented short fibers (Fig. 5d). Anisogels tethered with bicyclic RGD (K-P2), linear RGD (K-RGD) and fibronectin fragment (2  $\mu\text{M}$ , FN\*) have comparable FWHM of  $\sim 80^\circ$  with no statistical significance between them. We define that nerves are highly aligned when the FWHM  $< 90^\circ$ .<sup>56</sup> These observations are consistent with our previous report on fully PEG-based Anisogels tethered with fibronectin fragment.<sup>20</sup>

## Materials and methods


### Fabrication of PEG gels

8-Arm 20 kDa PEG (Jenkem Technology, USA) is conjugated separately with two types of peptides H-NQEQVSPLERCG-NH<sub>2</sub> (PEG-Q) and Ac-FKGG-GPQG↓IWGQ-ERCGNH<sub>2</sub> (PEG-K<sub>1</sub>) or alternative MMP-sensitive domains (Pepscan, Netherlands) bearing conjugated Q and K amino acids, respectively. A stoichiometric ratio of 0.477 w/v% PEG-Q and 0.522 w/v% PEG-K is crosslinked in the presence of activated Factor XIII, (20 U mL<sup>-1</sup>, CSL Behring GmbH, 1250 U FXIII). Factor XIII is activated with thrombin (200 U mL<sup>-1</sup>) buffered with 10 mM Tris, 25 mM CaCl<sub>2</sub>, 150 mM NaCl for 30 min at 37 °C (briefly vortexing every 5 min). A buffer solution (10 $\times$ , 0.1 M CaCl<sub>2</sub>, 0.5 M Tris, 1.1 M NaCl) is used to regulate the osmotic pressure of the gel precursor. All RGD-based bio-functional cell adhesive peptides are coupled to the gel at 100  $\mu\text{M}$  concentration of the final gel volume, resulting in a ratio of 1 : 24 between RGD peptides and total arms of star PEG molecules. In the case of complete peptide coupling, either 7.75% of the PEG-K arms would be tethered with RGD peptides or 8.46% of the PEG-Q arms, depending on the peptide domain used. The gels are incubated at 37 °C for 30 minutes for crosslinking and cultured in media.

### Peptide synthesis

First, the linear RGD-sequences and other integrin-selectivity-promoting peptides are synthesized *via* Fmoc-based solid-





**Fig. 5** Anisogels to induce nerve alignment in bicyclic RGD peptide tethered PEG gels. (A) DRG encapsulated in short fiber-based Anisogel, stained for  $\beta$ -tubulin (yellow) in PEG hydrogels with  $K_2$  MMP degradable crosslinker in combination with bicyclic RGD peptides (K-P2), linear RGD peptides (K-RGD), and 2  $\mu$ M fibronectin fragments (FN\*), scale bar 200  $\mu$ m. White arrows indicating the direction of magnetically oriented fibers. (B) Neurite distribution is plotted radially from 90 to  $-90^\circ$  revealing narrow distribution for bicyclic, linear, and fibronectin fragment around  $0^\circ$ . (C) Superimposed bright field and tubulin stained Anisogel with K-P2 revealing neurite alignment along the direction of the short anisometric PCL fibers. (D) Full width at half-maxima (FWHM,  $^\circ$ ) is quantified for neurite orientation distribution in DRGs with (short fiber-Anisogel) and without (control) and plotted among different biomolecules.

phase peptide-synthesis using a fully automated peptide synthesizer as described by Bernhagen *et al.*<sup>43</sup> Subsequently, these peptides are dissolved to 0.5  $\mu$ M concentration in a 1 : 3 mixture of acetonitrile (ACN)/MilliQ-water and mixed with  $\sim 1.1$  equivalent of tris(bromomethyl) benzene (T3; dissolved in pure ACN at 10 mM concentration) until homogeneity, and left at room temperature for 1 h. Then, the reaction is quenched with 10% TFA/H<sub>2</sub>O to pH < 4 and the reaction mixture is purified *via* preparative HPLC, followed by lyophilization. All peptides were produced in PEPSCAN. B.V, the Netherlands.

#### Encapsulation of cells in 3D hydrogel scaffolds and cell culture

L929 mouse-derived fibroblasts cells (ATCC, Germany) and DRGs from 10 days old embryonic chicks are harvested in RPMI and Hanks Balanced Salt Solution (HBSS, Gibco), respectively. In the case of single fibroblasts, the gel precursors are mixed with a pre-counted cell suspension in a defined volume, resulting in a cell concentration of 500  $\mu$ L<sup>-1</sup>. Individual DRGs are embedded manually into the hydrogel

precursors using tweezers. The cell encapsulated hydrogels or Anisogels are flipped every 10 minutes to ensure a homogeneous cell distribution and after 30 min, the gels are incubated with media at 37  $^\circ$ C to ensure complete precursor crosslinking before adding the media. The crosslinked gels are cultured for 7 days in RPMI basal medium, enriched with 10% Fetal Bovine Serum (FBS, Biowest) and 1% Antibiotic-Antimycotic (Gibco) for L929 cells and DMEM, enriched with 20 ng mL<sup>-1</sup> nerve growth factor, 10% fetal bovine serum (FBS, Biowest) and 1% Antibiotic-Antimycotic (Gibco) in the case of DRGs. The media is exchanged every two days, and the cell-loaded gels are cultured at 37  $^\circ$ C, 5% CO<sub>2</sub>, and 95% humidity.

#### Anisogel fabrication

Short magneto-responsive rod-shaped fibers are produced *via* solvent assisted spinning (SAS) based on previous reports.<sup>55</sup> A polymer solution with 17 w/v% polycaprolactone (PCL) is prepared by dissolving PCL in 50 : 50 v/v chloroform : acetic acid, while superparamagnetic iron oxide nanoparticles (SPIONS)



are dispersed into the solution before SAS.<sup>55</sup> The fibers are collected on a cylindrical rotating drum and harvested for cryo-cutting at desirable lengths. The fiber concentration in the PEG hydrogel precursor solution is approximately 1 v/v%. The Anisogel precursor mixture is cast on a DRG between two magnets generating a field of ~50 mT. This enables the fibers to align parallel to the magnetic field lines during crosslinking of the surrounding PEG-based hydrogel. The bulk matrix around the aligned fibers is allowed to crosslink for 30 minutes at 37 °C before adding more media.

### 3D immunofluorescent staining

All the incubation steps in this staining protocol are performed on a plate shaker (at 30 rpm) unless stated otherwise. Encapsulated cells in 3D gels are washed twice with PBS for 30 minutes and are fixed with 4% paraformaldehyde (PFA) in PBS for 1 h on a plate shaker. After fixing, the gels are washed twice with PBS for 1 h and treated with 0.1% TritonX-100 for 40 minutes, and further washed twice with PBS for 1 h. For L929 fibroblasts, the gels are treated with iFluor-phalloidin 488 or 594 (Abcam, Germany) (1:1000) in PBS in combination with DAPI (1:100) and incubated for 4 h. The gels are washed twice with PBS for 1 h each and stored until imaging. The encapsulated DRGs in the gel are blocked with 5% bovine serum albumin (BSA) (Sigma, Germany) in PBS for 4 h, followed by the addition of primary beta-tubulin antibody TUJ1 (BioLegend, USA) (1:250) in 5% BSA solution for 18 h. The gels are washed twice with PBS for 1 h before adding the secondary antibody Alexa Fluor 633 goat anti-mouse (Invitrogen, Germany) (1:1000) in PBS and DAPI (1:100). The secondary antibody solution is incubated for 4 h and washed twice for 1 h each and stored in PBS until imaging with confocal microscopy.

### Imaging

Laser scanning confocal microscopy (SP8 Tandem Confocal, Leica Microsystems Inc.) is used to image the Z stacks of the cells encapsulated in the hydrogel. Air objective of 10×/0.3 N.A magnification is used to obtain fluorescent micrographs by exciting the fluorophores at different wavelengths and obtaining the emission signals at multiple channels.

### Analysis of fibroblast growth

The Z stack images are converted into a maximum projection image using FIJI image J after the background calculated with a rolling ball filter (size = 20) has been subtracted. The image is then converted into an 8-bit image with an auto-Otsu threshold to convert the images to binary. These images are referred to as threshold images and the percentage of cell invasion areas is computed. Cell invasion here is quantified based on % of actin pixels per field of view or per image. This data can be a combination of cells that are spread, as well as rounded cells, taking cell proliferation into account. To obtain a smoothed image, the threshold images are further treated with a shape smoothing plugin (relative proportion fds = 5,

absolute number fds = 5). The edge effect is analyzed using the formula:

$$\text{Edge effect (\%)} = \frac{\text{area (\%)} \text{ of threshold cells} - \text{area (\%)} \text{ of smoothed cells}}{\sqrt{\text{area (\%)} \text{ of threshold cells}}}$$

In addition, each cell or cell cluster is analyzed for its circularity, after applying the 'Otsu' threshold, the images are processed using a particle analyzer tool (FIJI, Image J) for particle sizes >500 pixels. Hence, cells that are spreading well does not guarantee that they undergo similar proliferation and invasion rates. On the other hand, a large cell invasion does not always mean the cells are healthy and spreading. Cell invasion and the edge effect are both computed per field of view, while the circularity is measured for each cell or cell cluster. The data obtained from different gel conditions are compared and plotted in Origin.


### Analysis of neurite outgrowth

The Z stack images are converted into a maximum projection image using FIJI image J. The explant/core of the DRG is manually fitted into a mask and the position of the centroid of the mask is used as the 'center for radial analysis. The tubulin stained images are Gauss smoothed with a window radius of 5.0 pixels and a width of 1.0 pixel. Power law dynamic compression/expansion is applied with power 0.5. The binary images subtracted with the explant mask is used for radial analysis. The number of non-zero pixels as a function of distance (radius) is obtained, which is further computed to get pixel density = pixels per unit area. Neurite growth at half-maximum density is computed by measuring the distance between the edge of the DRG explant and the distance at which the neurite density reaches half-maximum. The longest distance travelled by nerve is defined as the distance from the edge of the DRG explant until the pixel density < 0.001 pixels per  $\mu\text{m}^2$  (Fig. 6).

### The orientation of neurites inside a PEG-based Anisogel

Neurites stained for  $\beta$ -tubulin are imaged as z-stack. Neurite alignment is quantified inside the 3D hydrogel starting 10  $\mu\text{m}$  above the first neurite in focus, starting from the bottom. A stack size of 100  $\mu\text{m}$  is imaged and the maximum z-projection is used for orientation analysis. The DRG core is converted into a mask, to remove from the image during orientation analysis. Neurite orientation is quantified using an elliptical Mexican hat filter (a Laplace operator applied on an elliptic two-dimensional Gaussian function) as previously reported.<sup>20</sup> The orientation kernels are designed to account for only the neurite data, excluding non-specific stains. The angles of the orientation kernels are plotted as a histogram and the maxima are set to zero to compare the relative distributions among other neurite orientations and thus using the full width at half-maximum (FWHM) as a measure of the degree of alignment of neurites in the Anisogels. Based on our previous





**Fig. 6** Analysis of neurite outgrowth using pixel density to compute the neurite length at half-maximum density and the longest distance travelled by nerve.

reports, lower FWHM [FWHM < 90°] indicate higher neurite alignment.<sup>56</sup>

### Statistics

Statistical analysis is performed in Origin 2016 for Windows. A one-way ANOVA is applied with *p*-values below 0.05 being considered significant in combination with Bonferroni correction.

## Conclusions

PEG hydrogels crosslinked with proteolytically degradable domains and RGD bicyclic peptides selective towards integrin subunits are investigated to improve fibroblast growth and nerve extension inside synthetic PEG-based hydrogels. The short bicyclic RGD peptides are easily tethered to the PEG hydrogels *via* their amine or glutamine linkers. Fibroblast cells in 3D PEG gels show high network like formation compared to cells in gels tethered with linear and cyclic RGD peptides. The bicyclic peptides significantly enhance nerve growth (at half-maximum density) length (~600 μm) and the longest distance travelled (~1200 μm), when compared to linear and monocyclic RGD peptides. In the case of nerve growth, the  $\alpha_v\beta_3$  selective P2 bicyclic peptides slightly outperformed the engineered fibronectin fragment FNIII9\*-10/12-14, however not significantly. Degradable MMP cleavable crosslinkers incorporated in the gels with bicyclic RGD peptides improve cell invasion for K<sub>1</sub> (GPQG↓IWGQ) and K<sub>2</sub> (VPMS↓MRGG) MMP degradable crosslinkers and a marginal increase in cell growth for both fibroblasts and nerves in the case of K<sub>2</sub>. This report demonstrates for the first time the large potential of bicyclic RGD peptides inside PEG-based hydrogels, showing superior fibroblast and nerve growth compared to linear and monocyclic RGD peptides. Including oriented magneto-responsive short fibers inside bicyclic RGD-modified Anisogels demon-

strates highly aligned nerve growth in the direction along the oriented fibers comparable to Anisogels modified with the fibronectin fragment.

## Author contributions

S.V carried out the experiments supervised by L.D.L based on the gels optimized by C.L and A.C.N using the bicyclic peptides designed by D.B and P.T. PCL fibers for the Anisogels were provided by A.O-A. The neurite growth and orientation were computationally analyzed by T.H. Manuscript was written by S.V with support from L.D.L. All the authors contributed in the manuscript.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We thank J. Huffel for experimental assistance and C. Bergerbit for his support in writing. We acknowledge funding from the European Union's Horizon 2020 research and innovation programme under Marie Skłodowska-Curie grant agreement no. 642687 (Biogel). We gratefully acknowledge funding from the Leibniz Senate Competition Committee (SAW) under the Professorinnenprogramm (SAW-2017-PB62: BioMat). We acknowledge funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (ANISOGEL, grant agreement no. 637853). This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 874586 (Organtrans).

## References

- 1 S. Cheng, E. C. Clarke and L. E. Bilston, *Med. Eng. Phys.*, 2008, **30**, 1318–1337.
- 2 M. J. Blewitt and R. K. Willits, *Ann. Biomed. Eng.*, 2007, **35**, 2159–2167.
- 3 G. Huang, F. Li, X. Zhao, Y. Ma, Y. Li, M. Lin, G. Jin, T. J. Lu, G. M. Genin and F. Xu, *Chem. Rev.*, 2017, **117**, 12764–12850.
- 4 K. M. Yamada and M. Sixt, *Nat. Rev. Mol. Cell Biol.*, 2019, **20**, 738–752.
- 5 T. Nakaji-Hirabayashi, K. Kato and H. Iwata, *Bioconjugate Chem.*, 2012, **23**, 212–221.
- 6 D. Hodde, J. Gerardo-Nava, V. Wöhlk, S. Weinandy, S. Jockenhövel, A. Kriebel, H. Altinova, H. W. M. Steinbusch, M. Möller, J. Weis, J. Mey and G. A. Brook, *Eur. J. Neurosci.*, 2016, **43**, 376–387.



- 7 A. R. Bento, P. Quelhas, M. J. Oliveira, A. P. Pêgo and I. F. Amaral, *J. Tissue Eng. Regener. Med.*, 2017, **11**, 3494–3507.
- 8 S. Li, L. R. Nih, H. Bachman, P. Fei, Y. Li, E. Nam, R. Dimatteo, S. T. Carmichael, T. H. Barker and T. Segura, *Nat. Mater.*, 2017, **16**, 953–961.
- 9 N. Broguiere, L. Isenmann and M. Zenobi-Wong, *Biomaterials*, 2016, **99**, 47–55.
- 10 V. Carriel, J. Garrido-Gómez, P. Hernández-Cortés, I. Garzón, S. García-García, J. A. Sáez-Moreno, M. Del Carmen Sánchez-Quevedo, A. Campos and M. Alaminos, *J. Neural Eng.*, 2013, **10**, 026022.
- 11 K. Chwalek, D. Sood, W. L. Cantley, J. D. White, M. Tang-Schomer and D. L. Kaplan, *J. Visualized Exp.*, 2015, **2015**, 1–7.
- 12 J. Zhu and R. E. Marchant, *Expert Rev. Med. Devices*, 2011, **8**, 607–626.
- 13 E. F. Plow, T. A. Haas, L. Zhang, J. Loftus and J. W. Smith, *J. Biol. Chem.*, 2000, **275**, 21785–21788.
- 14 K. J. Lampe, A. L. Antaris and S. C. Heilshorn, *Acta Biomater.*, 2013, **9**, 5590–5599.
- 15 Y. Berkovitch and D. Seliktar, *Int. J. Pharm.*, 2017, **523**, 545–555.
- 16 B. P. dos Santos, B. Garbay, M. Fenelon, M. Rosselin, E. Garanger, S. Lecommandoux, H. Oliveira and J. Amédée, *Acta Biomater.*, 2019, **99**, 154–167.
- 17 A. M. Hopkins, L. De Laporte, F. Tortelli, E. Spedden, C. Staii, T. J. Atherton, J. A. Hubbell and D. L. Kaplan, *Adv. Funct. Mater.*, 2013, **23**, 5140–5149.
- 18 G. Palazzolo, N. Broguiere, O. Cenciarelli, H. Dermutz and M. Zenobi-Wong, *Tissue Eng., Part A*, 2015, **21**, 2177–2185.
- 19 R. Boni, A. Ali, A. Shavandi and A. N. Clarkson, *J. Biomed. Sci.*, 2018, **25**, 1–21.
- 20 C. Licht, J. C. Rose, A. O. Anarkoli, D. Blondel, M. Roccio, T. Haraszti, D. B. Gehlen, J. A. Hubbell, M. P. Lutolf and L. De Laporte, *Biomacromolecules*, 2019, **20**, 4075–4087.
- 21 P. Naghdi, T. Tiraihi, F. Ganji, S. Darabi, T. Taheri and H. Kazemi, *J. Tissue Eng. Regener. Med.*, 2016, **10**, 199–208.
- 22 R.-S. Hsu, P.-Y. Chen, J.-H. Fang, Y.-Y. Chen, C.-W. Chang, Y.-J. Lu and S.-H. Hu, *Adv. Sci.*, 2019, **6**, 1900520.
- 23 X. Li, E. Katsanevakis, X. Liu, N. Zhang and X. Wen, *Prog. Polym. Sci.*, 2012, **37**, 1105–1129.
- 24 J. Patterson and J. A. Hubbell, *Biomaterials*, 2010, **31**, 7836–7845.
- 25 K. Bott, Z. Upton, K. Schrobback, M. Ehrbar, J. A. Hubbell, M. P. Lutolf and S. C. Rizzi, *Biomaterials*, 2010, **31**, 8454–8464.
- 26 V. Truong, I. Blakey and A. K. Whittaker, *Biomacromolecules*, 2012, **13**, 4012–4021.
- 27 M. Ehrbar, S. C. Rizzi, R. Hlushchuk, V. Djonov, A. H. Zisch, J. A. Hubbell, F. E. Weber and M. P. Lutolf, *Biomaterials*, 2007, **28**, 3856–3866.
- 28 M. P. Lutolf, J. L. Lauer-Fields, H. G. Schmoekel, A. T. Metters, F. E. Weber, G. B. Fields and J. A. Hubbell, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**, 5413–5418.
- 29 M. M. Martino, F. Tortelli, M. Mochizuki, S. Traub, D. Ben-David, G. A. Kuhn, R. Müller, E. Livne, S. A. Eming and J. A. Hubbell, *Sci. Transl. Med.*, 2011, **3**(100), 100ra89.
- 30 M. Ehrbar, S. C. Rizzi, R. G. Schoenmakers, J. A. Hubbell, F. E. Weber and M. P. Lutolf, *Biomacromolecules*, 2007, **8**, 3000–3007.
- 31 B. Geiger, J. P. Spatz and A. D. Bershadsky, *Nat. Rev. Mol. Cell Biol.*, 2009, **10**, 21–33.
- 32 F. G. Giancotti and E. Ruoslahti, *Science*, 1999, **285**, 1028LP–1033.
- 33 M. A. Dechantsreiter, E. Planker, B. Mathä, E. Lohof, G. Hölzemann, A. Jonczyk, S. L. Goodman and H. Kessler, *J. Med. Chem.*, 1999, **42**, 3033–3040.
- 34 C. Mas-Moruno, R. Fraioli, F. Rechenmacher, S. Neubauer, T. G. Kapp and H. Kessler, *Angew. Chem., Int. Ed.*, 2016, **55**, 7048.
- 35 T. G. Kapp, F. Rechenmacher, S. Neubauer, O. V. Maltsev, E. A. Cavalcanti-Adam, R. Zarka, U. Reuning, J. Notni, H. J. Wester, C. Mas-Moruno, J. Spatz, B. Geiger and H. Kessler, *Sci. Rep.*, 2017, **7**, 1–13.
- 36 M. Kantlehner, P. Schaffner, D. Finsinger, J. Meyer, A. Jonczyk, B. Diefenbach, B. Nies, G. Hölzemann, S. L. Goodman and H. Kessler, *Angew. Chem., Int. Ed.*, 2000, **39**, 107–114.
- 37 D. Pallarola, A. Bochen, H. Boehm, F. Rechenmacher, T. R. Sobahi, J. P. Spatz and H. Kessler, *Adv. Funct. Mater.*, 2014, **24**, 943–956.
- 38 S. Neubauer, F. Rechenmacher, R. Brimiouille, F. S. Di Leva, A. Bochen, T. R. Sobahi, M. Schottelius, E. Novellino, C. Mas-Moruno, L. Marinelli and H. Kessler, *J. Med. Chem.*, 2014, **57**, 3410–3417.
- 39 D. Heckmann, A. Meyer, B. Laufer, G. Zahn, R. Stragies and H. Kessler, *ChemBioChem*, 2008, **9**, 1397–1407.
- 40 H. B. Schiller, M. R. Hermann, J. Polleux, T. Vignaud, S. Zanivan, C. C. Friedel, Z. Sun, A. Raducanu, K. E. Gottschalk, M. Théry, M. Mann and R. Fässler, *Nat. Cell Biol.*, 2013, **15**, 625–636.
- 41 C. Diaz, S. Neubauer, F. Rechenmacher, H. Kessler and D. Missirlis, *J. Cell Sci.*, 2020, **133**, jcs232702.
- 42 D. Bernhagen, V. Jungbluth, N. G. Quilis, J. Dostalek, P. B. White, K. Jalink and P. Timmerman, *ACS Comb. Sci.*, 2019, **21**, 198–206.
- 43 D. Bernhagen, V. Jungbluth, N. G. Quilis, J. Dostalek, P. B. White, K. Jalink and P. Timmerman, *ACS Comb. Sci.*, 2019, **21**, 598–607.
- 44 F. Cipriani, D. Bernhagen, C. Garcia-Arévalo, I. G. De Torre, P. Timmerman and J. C. Rodriguez-Cabello, *Biomed. Mater.*, 2019, **14**, 035009.
- 45 B. H. Hu and P. B. Messersmith, *J. Am. Chem. Soc.*, 2003, **125**, 14298–14299.
- 46 J. Patterson and J. A. Hubbell, *Biomaterials*, 2011, **32**, 1301–1310.



- 47 D. Bernhagen, V. Jungbluth, N. G. Quilis, J. Dostalek, P. B. White, K. Jalink and P. Timmerman, *ACS Comb. Sci.*, 2019, **21**, 198–206.
- 48 E. H. J. Danen, S. I. Aota, A. A. Van Kraats, K. M. Yamada, D. J. Ruiter and G. N. P. Van Muijen, *J. Biol. Chem.*, 1995, **270**, 21612–21618.
- 49 X. K. Zhao, Y. Cheng, M. Liang Cheng, L. Yu, M. Mu, H. Li, Y. Liu, B. Zhang, Y. Yao, H. Guo, R. Wang and Q. Zhang, *Sci. Rep.*, 2016, **6**, 19276.
- 50 J. C. Rose, D. B. Gehlen, T. Haraszti, J. Köhler, C. J. Licht and L. De Laporte, *Biomaterials*, 2018, **163**, 128–141.
- 51 P. M. Yip, X. Zhao, A. M. P. Montgomery and C. H. Siu, *Mol. Biol. Cell*, 1998, **9**, 277–290.
- 52 M. Delannet, F. Martin, B. Bossy, D. A. Cheresch, L. F. Reichardt and J. L. Duband, *Development*, 1994, **120**, 2687–2702.
- 53 D. O. Clegg, K. L. Wingerd, S. T. Hikita and E. C. Tolhurst, *Front. Biosci.*, 2003, **8**, d723-50.
- 54 A. Omidinia-anarkoli, R. Rimal, Y. Chandorkar, D. B. Gehlen, L. De Laporte, J. C. Rose and K. Rahimi, DOI: 10.1021/acsami.8b17955.
- 55 A. Omidinia-Anarkoli, S. Boesveld, U. Tuvshindorj, J. C. Rose, T. Haraszti and L. De Laporte, *Small*, 2017, **13**, 1–8.
- 56 J. C. Rose, D. B. Gehlen, A. Omidinia-Anarkoli, M. Fölster, T. Haraszti, E. E. Jaekel and L. De Laporte, *Adv. Healthcare Mater.*, 2020, **2000886**, 2000886.

